Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC). Patients with mCRC and unsuccessful previous oxaliplatin-base...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2014-07, Vol.31 (7), p.35, Article 35 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 35 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 31 |
| creator | Xie, Song Han, Guoping Fan, Zhikun He, Lifeng Xu, Wenbing Qin, Zhen |
| description | We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC). Patients with mCRC and unsuccessful previous oxaliplatin-based chemotherapy were included in the study. The FOLFIRI arm was given FOLFIRI only. The FOLFIRI+PB arm was given panitumumab (3 mg/kg) and bevacizumab (3 mg/kg) plus FOLFIRI every other week. Between 2009 and 2013, 155 and 137 patients were included in the FOLFIRI arm and FOLFIRI+PB arm, respectively. The response rate was 40.1 % for FOLFIRI+PB arm versus 30.1 % for FOLFIRI arm. The disease-controlled rate in FOLFIRI+PB arm was improved to 62.2 from 50.2 % in FOLFIRI arm. The median overall survival was 13.9 months in FOLFIRI+PB arm as compared to 10.7 months in FOLFIRI arm. A series of adverse events were comparable between two arms, whereas some of the antibody therapy-associated toxicities were observed in FOLFIRI+PB arm. The new strategy of combining panitumumab and bevacizumab with FOLFIRI as second-line chemotherapy for patients with mCRC is safe and feasible. |
| doi_str_mv | 10.1007/s12032-014-0035-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1542291985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3359895121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-d9fc988c2e3f5a6f09c41aa98e15faaf982147e1c94818de7f486d08144accc43</originalsourceid><addsrcrecordid>eNp1kd2KFDEQhRtR3B99AG8k4I2C0VQ6mU4uZXHWgYEFf8C7JpOuaJbuZEzSyvh8PpiZ6VW88SqpqlPnozhN8wTYK2Cse52Bs5ZTBoIy1kra3mvOQUpNoYXP9-u_lR1lcsXOmoucbxnjILl-2JxxoUEqrc-bXx-Mw3IgJgwEnfPW2AOJjmS0MQx09AFJSWjKhKGQH758JS7WrrfEWD-8JJK6cY4pzqnW48nHJx9iQWsCeb6-2a437zcviA_Exmnngyk-hiNib4Iv8zRPZnda2-H3avHzVLuY6rz4Cs0LdcJicqktW33GmNAWM5LKsJgeNQ-cGTM-vnsvm0_rtx-v3tHtzfXm6s2W2rbjhQ7aWa2U5dg6aVaOaSvAGK0QpDPGacVBdAhWCwVqwM4JtRqYAiGMtVa0l82zxXef4rcZc-lv692hInuQgnMNWsmqgkVlU8w5oev3yU8mHXpg_TG3fsmtr7n1x9z6tu48vXOedxMOfzf-BFUFfBHkOgpfMP2D_q_rb4PIpv0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1542291985</pqid></control><display><type>article</type><title>Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Xie, Song ; Han, Guoping ; Fan, Zhikun ; He, Lifeng ; Xu, Wenbing ; Qin, Zhen</creator><creatorcontrib>Xie, Song ; Han, Guoping ; Fan, Zhikun ; He, Lifeng ; Xu, Wenbing ; Qin, Zhen</creatorcontrib><description>We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC). Patients with mCRC and unsuccessful previous oxaliplatin-based chemotherapy were included in the study. The FOLFIRI arm was given FOLFIRI only. The FOLFIRI+PB arm was given panitumumab (3 mg/kg) and bevacizumab (3 mg/kg) plus FOLFIRI every other week. Between 2009 and 2013, 155 and 137 patients were included in the FOLFIRI arm and FOLFIRI+PB arm, respectively. The response rate was 40.1 % for FOLFIRI+PB arm versus 30.1 % for FOLFIRI arm. The disease-controlled rate in FOLFIRI+PB arm was improved to 62.2 from 50.2 % in FOLFIRI arm. The median overall survival was 13.9 months in FOLFIRI+PB arm as compared to 10.7 months in FOLFIRI arm. A series of adverse events were comparable between two arms, whereas some of the antibody therapy-associated toxicities were observed in FOLFIRI+PB arm. The new strategy of combining panitumumab and bevacizumab with FOLFIRI as second-line chemotherapy for patients with mCRC is safe and feasible.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-014-0035-3</identifier><identifier>PMID: 24915899</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject><![CDATA[Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Female ; Fluorouracil - therapeutic use ; Hematology ; Humans ; Internal Medicine ; Leucovorin - administration & dosage ; Leucovorin - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Organoplatinum Compounds - administration & dosage ; Original Paper ; Pathology ; Treatment Outcome ; Young Adult]]></subject><ispartof>Medical oncology (Northwood, London, England), 2014-07, Vol.31 (7), p.35, Article 35</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-d9fc988c2e3f5a6f09c41aa98e15faaf982147e1c94818de7f486d08144accc43</citedby><cites>FETCH-LOGICAL-c372t-d9fc988c2e3f5a6f09c41aa98e15faaf982147e1c94818de7f486d08144accc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-014-0035-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-014-0035-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24915899$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xie, Song</creatorcontrib><creatorcontrib>Han, Guoping</creatorcontrib><creatorcontrib>Fan, Zhikun</creatorcontrib><creatorcontrib>He, Lifeng</creatorcontrib><creatorcontrib>Xu, Wenbing</creatorcontrib><creatorcontrib>Qin, Zhen</creatorcontrib><title>Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC). Patients with mCRC and unsuccessful previous oxaliplatin-based chemotherapy were included in the study. The FOLFIRI arm was given FOLFIRI only. The FOLFIRI+PB arm was given panitumumab (3 mg/kg) and bevacizumab (3 mg/kg) plus FOLFIRI every other week. Between 2009 and 2013, 155 and 137 patients were included in the FOLFIRI arm and FOLFIRI+PB arm, respectively. The response rate was 40.1 % for FOLFIRI+PB arm versus 30.1 % for FOLFIRI arm. The disease-controlled rate in FOLFIRI+PB arm was improved to 62.2 from 50.2 % in FOLFIRI arm. The median overall survival was 13.9 months in FOLFIRI+PB arm as compared to 10.7 months in FOLFIRI arm. A series of adverse events were comparable between two arms, whereas some of the antibody therapy-associated toxicities were observed in FOLFIRI+PB arm. The new strategy of combining panitumumab and bevacizumab with FOLFIRI as second-line chemotherapy for patients with mCRC is safe and feasible.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kd2KFDEQhRtR3B99AG8k4I2C0VQ6mU4uZXHWgYEFf8C7JpOuaJbuZEzSyvh8PpiZ6VW88SqpqlPnozhN8wTYK2Cse52Bs5ZTBoIy1kra3mvOQUpNoYXP9-u_lR1lcsXOmoucbxnjILl-2JxxoUEqrc-bXx-Mw3IgJgwEnfPW2AOJjmS0MQx09AFJSWjKhKGQH758JS7WrrfEWD-8JJK6cY4pzqnW48nHJx9iQWsCeb6-2a437zcviA_Exmnngyk-hiNib4Iv8zRPZnda2-H3avHzVLuY6rz4Cs0LdcJicqktW33GmNAWM5LKsJgeNQ-cGTM-vnsvm0_rtx-v3tHtzfXm6s2W2rbjhQ7aWa2U5dg6aVaOaSvAGK0QpDPGacVBdAhWCwVqwM4JtRqYAiGMtVa0l82zxXef4rcZc-lv692hInuQgnMNWsmqgkVlU8w5oev3yU8mHXpg_TG3fsmtr7n1x9z6tu48vXOedxMOfzf-BFUFfBHkOgpfMP2D_q_rb4PIpv0</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Xie, Song</creator><creator>Han, Guoping</creator><creator>Fan, Zhikun</creator><creator>He, Lifeng</creator><creator>Xu, Wenbing</creator><creator>Qin, Zhen</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140701</creationdate><title>Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer</title><author>Xie, Song ; Han, Guoping ; Fan, Zhikun ; He, Lifeng ; Xu, Wenbing ; Qin, Zhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-d9fc988c2e3f5a6f09c41aa98e15faaf982147e1c94818de7f486d08144accc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xie, Song</creatorcontrib><creatorcontrib>Han, Guoping</creatorcontrib><creatorcontrib>Fan, Zhikun</creatorcontrib><creatorcontrib>He, Lifeng</creatorcontrib><creatorcontrib>Xu, Wenbing</creatorcontrib><creatorcontrib>Qin, Zhen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xie, Song</au><au>Han, Guoping</au><au>Fan, Zhikun</au><au>He, Lifeng</au><au>Xu, Wenbing</au><au>Qin, Zhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>31</volume><issue>7</issue><spage>35</spage><pages>35-</pages><artnum>35</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC). Patients with mCRC and unsuccessful previous oxaliplatin-based chemotherapy were included in the study. The FOLFIRI arm was given FOLFIRI only. The FOLFIRI+PB arm was given panitumumab (3 mg/kg) and bevacizumab (3 mg/kg) plus FOLFIRI every other week. Between 2009 and 2013, 155 and 137 patients were included in the FOLFIRI arm and FOLFIRI+PB arm, respectively. The response rate was 40.1 % for FOLFIRI+PB arm versus 30.1 % for FOLFIRI arm. The disease-controlled rate in FOLFIRI+PB arm was improved to 62.2 from 50.2 % in FOLFIRI arm. The median overall survival was 13.9 months in FOLFIRI+PB arm as compared to 10.7 months in FOLFIRI arm. A series of adverse events were comparable between two arms, whereas some of the antibody therapy-associated toxicities were observed in FOLFIRI+PB arm. The new strategy of combining panitumumab and bevacizumab with FOLFIRI as second-line chemotherapy for patients with mCRC is safe and feasible.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24915899</pmid><doi>10.1007/s12032-014-0035-3</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2014-07, Vol.31 (7), p.35, Article 35 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_1542291985 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Camptothecin - analogs & derivatives Camptothecin - therapeutic use Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Female Fluorouracil - therapeutic use Hematology Humans Internal Medicine Leucovorin - administration & dosage Leucovorin - therapeutic use Male Medicine Medicine & Public Health Middle Aged Oncology Organoplatinum Compounds - administration & dosage Original Paper Pathology Treatment Outcome Young Adult |
| title | Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A42%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20second-line%20treatment%20with%20folinic%20acid,%205-fluorouracil%20and%20irinotecan%20(FOLFIRI)%20in%20combination%20of%20panitumumab%20and%20bevacizumab%20for%20patients%20with%20metastatic%20colorectal%20cancer&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Xie,%20Song&rft.date=2014-07-01&rft.volume=31&rft.issue=7&rft.spage=35&rft.pages=35-&rft.artnum=35&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-014-0035-3&rft_dat=%3Cproquest_cross%3E3359895121%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1542291985&rft_id=info:pmid/24915899&rfr_iscdi=true |